ACAD Stock Forecast & Price Target

Acadia Pharmaceuticals is supported by a strong commercial base in NUPLAZID and DAYBUE, with 3Q26 revenue estimated at $335.4M versus FactSet’s $332.5M, including $198.7M from NUPLAZID and $136.6M from DAYBUE, while longer-term sales potential remains compelling at roughly $600M for NUPLAZID in 2027 and about $700M for DAYBUE by 2030. Its outlook is further strengthened by a deep pipeline, as remlifanserin showed a narrow miss on the Phase 2 primary endpoint in Alzheimer’s disease psychosis but delivered nominal secondary endpoint significance, clean safety with no QT prolongation, and a more pronounced signal in the higher-baseline psychosis subgroup that may improve Phase 3 success. The company also has multiple late-stage assets and upcoming catalysts, including detailed RADIANT data presentation at the Clinical Trials on Alzheimer’s Disease conference in November 2026, which together support a favorable long-term fundamental view despite trial-design uncertainty.

Acadia Pharmaceuticals is facing a fragile outlook because its growth depends on a narrow set of products and high-risk pipeline assets, while key programs in schizophrenia negative symptoms, ACP-204 for ADP, and ACP-101 for PWS could fail or be delayed. Commercially, Nuplazid’s growth in PPD may slow and Daybue’s launch in Rett syndrome may stall, leaving the company exposed if either franchise underperforms relative to market size, penetration, or pricing assumptions. With CNS drug development historically carrying a high failure rate and competition from larger biotech and pharmaceutical firms, adverse clinical or regulatory news could pressure financial projections and undermine valuation.